KLISBio, a clinical-stage company leading a revolution in restorative surgical procedures and tissue engineering, is willing to connect with investors and strategic partners, with the purpose of moving science forward and advancing innovation in the life science and healthcare domain with SILKBridge, KLISBio’s first product in pipeline for peripheral nerve repair.

SILKBridge is an absorbable medical device made of Bombyx mori silk fibroin and is intended for the surgical repair of peripheral nerve discontinuities to support regeneration across the defect. SILKBridge is expected to be available for clinical use in the US market in 2023. The tissue engineered technology at the core of SILKBridge merges a deep-rooted cultural tradition and know-how with the most advanced technologies creating a highly purified material required for biomedical applications, without the need for chemical cross-linking reactions that alter silk fibroin.

“KLISBio is driven by the desire to innovate and redesign therapeutic approaches to help improve people's sensory perception and daily functional activities that crucially define their quality of life.”, said Gabriele Grecchi, CEO and co-founder.

KLISBio is powered by an international group of world leaders in MedTech including Grecchi, CEO; Antonio Alessandrino, President & Chief Technology Officer; Giuliano Freddi, Chief Scientific Officer; Jason Schense, Chief Business Officer and Chief Operating Officer. The company recently announced that Rodrigo Bianchi will serve as Chairman of the Board, coming to KLISBio with more than three decades’ experience in global healthcare.

In addition to the strong leadership team, KLISBio works with physicians, engineers, researchers, chemists and biologists worldwide who represent excellence in the biomedical space. The company holds patents in Silk regenerated Fibroin + Native Silk Fibroin Pairing, Silk-based Composites and Core-Shell Silk Nanofibers.